Mobile

A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg i...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007789-51

A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg in Healthy Adolescents Aged 11 to 18 Years

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immunogenicity of 60 µg,, 120 µg,, and 200 μg rLP2086 vaccine as measured by SBA performed with MnB strains expressing LP2086 subfamily A and B proteins in healthy adolescents aged 11 to 18 years.

Critère d'inclusion

  • The test is a vaccine. The subjects are healthy adolescents

Liens